LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

LLY

922.39

-1.51%↓

JNJ

186.29

-0.03%↓

UNH

324.11

+0.82%↑

NVS

126.28

-0.09%↓

ABT

126.19

+1.02%↑

Начало・Списък с акции・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Затворен

СекторЗдравеопазване

8.85 -0.78

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.69

Максимум

8.93

Ключови измерители
By Trading Economics
Приходи	-2.7M -24M
Продажби	29M 155M
Марж на печалбата	-15.787
Служители	499
EBITDA	-1M -5.8M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+78.43% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	461M 2.3B
Предишно отваряне	9.63
Предишно затваряне	8.85

Настроения в новините

By Acuity

20%

80%

39 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

5.925 / 7.38 Подкрепа & съпротива

Amicus Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.11.2025 г., 21:06 ч. UTC

Значими двигатели на пазара

JBS Down After Trump Calls for Probe into Meat-Packing Companies

7.11.2025 г., 22:36 ч. UTC

Печалби

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

7.11.2025 г., 22:22 ч. UTC

Печалби

The Score: GM, Tesla, Palantir, American Airlines and More Stocks That Defined the Week -- WSJ

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Rev $2.95B >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q Net $210M >CSU.T

7.11.2025 г., 22:03 ч. UTC

Печалби

Constellation Software 3Q EPS $9.89 >CSU.T

7.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

7.11.2025 г., 20:59 ч. UTC

Печалби

Palantir's CEO Says His Earnings Were the Best Ever. They Weren't Even the Best of the Week. -- Barrons.com

7.11.2025 г., 20:26 ч. UTC

Пазарно говорене

Natural U.S. Gas Futures Extend Rally to Three Weeks -- Market Talk

7.11.2025 г., 20:22 ч. UTC

Печалби

Free-Spending Big Tech Dominates Earnings. As for the Rest: Don't Miss. -- Barrons.com

7.11.2025 г., 20:04 ч. UTC

Пазарно говорене

Oil Futures Close Choppy Week With Losses -- Market Talk

7.11.2025 г., 19:34 ч. UTC

Пазарно говорене

Gold Posts Small Gain for Week -- Market Talk

7.11.2025 г., 19:31 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Prices of Gas-Fired Power Plants Have Room to Grow -- Market Talk

7.11.2025 г., 19:17 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Tesla, Expedia, Take-Two, Block, Affirm, Sunrun, Globus Medical, JFrog, and More -- Barrons.com

7.11.2025 г., 19:09 ч. UTC

Печалби

Wendy's Turnaround Won't Be Easy. Earnings, and the Stock, Tell the Story. -- Barrons.com

7.11.2025 г., 19:08 ч. UTC

Печалби

KKR Defied Private-Equity Fundraising Slump in the Third Quarter -- WSJ

7.11.2025 г., 18:31 ч. UTC

Пазарно говорене

U.S. Oil RIg Count Unchanged at 414 -- Market Talk

7.11.2025 г., 17:27 ч. UTC

Пазарно говорене

EPA Announces New Exemptions to Biofuel Blending Rules -- Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Eli Lilly GLP-1 Deal with Trump Administration Provides Net Boost -- Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

7.11.2025 г., 17:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

7.11.2025 г., 17:17 ч. UTC

Придобивния, сливания и поглъщания

Satair Expects to Complete Purchase in Early 2026

7.11.2025 г., 17:17 ч. UTC

Придобивния, сливания и поглъщания

Satair: Deal Includes Unical's and ecube's Seven Operational Sites and Offices, With Combined 2024 Rev of $298M and Headcount of 413

7.11.2025 г., 17:15 ч. UTC

Придобивния, сливания и поглъщания

Airbus Unit Satair to Buy Unical Aviation From Platinum Equity

7.11.2025 г., 17:09 ч. UTC

Пазарно говорене

PENN Is Falling Further Behind Competitors -- Market Talk

7.11.2025 г., 16:49 ч. UTC

Пазарно говорене

Losing ESPN Partnership Will Hurt PENN -- Market Talk

7.11.2025 г., 16:24 ч. UTC

Пазарно говорене

OPEC+'s Output Hike Pause Comes Amid Excess Supply, Lower Spare Capacity -- Market Talk

7.11.2025 г., 16:17 ч. UTC

Пазарно говорене

Oil Market Faces Oversupply But "Glut" Might Be Overblown -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Amicus Therapeutics Inc Прогноза

Ценова цел

By TipRanks

78.43% нагоре

12-месечна прогноза

Среден 15.88 USD 78.43%

Висок 21 USD

Нисък 11 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Amicus Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Amicus Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.925 / 7.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

39 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.